Clinical trial CodeBreaK 301
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus Investigator's Choice Chemotherapy (FOLFOX or FOLFIRI) with or without Bevacizumab-awwb for Treatment-naïve Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Amgen |
| EudraCT Identifier | 2022-502352-31-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06252649 |
| Last update |